Increased Carrier Concentration in Zno/Cui Heterojunction Diode
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Physicochemical Properties of Organic Medicinal Agents
Principles of Drug Action 1, Spring 2005, Esters ESTERS AND RELATED CARBOXYLIC ACID DERIVATIVES Jack DeRuiter I. Structure and Preparation Esters are derivatives of carboxylic acids that arise via replacement of the hydroxyl (OH) portion of the acid COOH function with an "ether" moiety (-OR): O O H C C O C O Acid Ester Note that replacement of the acid OH group with an "ether" moiety removes the acidic function from the parent structure (acid) resulting in the formation of non-acidic (neutral, but somewhat polar) compounds (esters). Esters can be sub-classified based on their general structure as aliphatic, aromatic or cyclic (called "lactones") as illustrated by the examples below: O O CH2CH3 CH2CH3 O CH3 O O O Aliphatic Ester Aromatic Ester Cyclic Ester (Lactone) A variety of methods have been developed for the preparation of esters. Most of these methods involve reaction of an alcohol with an "activated carboxylic acid" compound (i.e. acid chloride): O O H C C X OC C O X- Ester "Activated" acid (X=Cl) Alcohol (Electrophile) (Nucleophile) The ester functionality does not introduce a center of asymmetry and thus optical and geometric isomerism does not result from the presence of this functional group. The ester functionality (the carbonyl and ether oxygen) is composed of an sp2 hybridized carbon so it cannot be chiral, and since there is free rotation about the ether bond geometric isomerism also is not possible at the sp2 center. 1 Principles of Drug Action 1, Spring 2005, Esters II. Solubility of Esters Esters contain carbonyl (C=O) and ether (O-C) dipoles arising from covalent bonding between electronegative oxygen atoms and electronically neutral carbon atoms. -
Biosynthesis of Natural Products Containing Β-Amino Acids
Natural Product Reports Biosynthesis of natural products containing β -amino acids Journal: Natural Product Reports Manuscript ID: NP-REV-01-2014-000007.R1 Article Type: Review Article Date Submitted by the Author: 21-Apr-2014 Complete List of Authors: Kudo, Fumitaka; Tokyo Institute Of Technology, Department of Chemistry Miyanaga, Akimasa; Tokyo Institute Of Technology, Department of Chemistry Eguchi, T; Tokyo Institute Of Technology, Department of Chemistry and Materials Science Page 1 of 20 Natural Product Reports NPR RSC Publishing REVIEW Biosynthesis of natural products containing βββ- amino acids Cite this: DOI: 10.1039/x0xx00000x Fumitaka Kudo, a Akimasa Miyanaga, a and Tadashi Eguchi *b Received 00th January 2014, We focus here on β-amino acids as components of complex natural products because the presence of β-amino acids Accepted 00th January 2014 produces structural diversity in natural products and provides characteristic architectures beyond that of ordinary DOI: 10.1039/x0xx00000x α-L-amino acids, thus generating significant and unique biological functions in nature. In this review, we first survey the known bioactive β-amino acid-containing natural products including nonribosomal peptides, www.rsc.org/ macrolactam polyketides, and nucleoside-β-amino acid hybrids. Next, the biosynthetic enzymes that form β-amino acids from α-amino acids and de novo synthesis of β-amino acids are summarized. Then, the mechanisms of β- amino acid incorporation into natural products are reviewed. Because it is anticipated that the rational swapping of the β-amino acid moieties with various side chains and stereochemistries by biosynthetic engineering should lead to the creation of novel architectures and bioactive compounds, the accumulation of knowledge regarding β- amino acid-containing natural product biosynthetic machinery could have a significant impact in this field. -
New Conceptual Understanding of Lewis Acidity, Coordinate Covalent Bonding, and Catalysis Joshua A
Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Summer 2009 New Conceptual Understanding of Lewis Acidity, Coordinate Covalent Bonding, and Catalysis Joshua A. Plumley Follow this and additional works at: https://dsc.duq.edu/etd Recommended Citation Plumley, J. (2009). New Conceptual Understanding of Lewis Acidity, Coordinate Covalent Bonding, and Catalysis (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1052 This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact [email protected]. NEW CONCEPTUAL UNDERSTANDING OF LEWIS ACIDITY, COORDINATE COVALENT BONDING, AND CATALYSIS A Dissertation Submitted to the Bayer School of Natural and Environmental Sciences Duquesne University In partial fulfillment of the requirements for the degree of Doctor of Philosophy By Joshua A. Plumley August 2009 NEW CONCEPTUAL UNDERSTANDING OF LEWIS ACIDITY, COORDINATE COVALENT BONDING, AND CATALYSIS By Joshua A. Plumley Approved August 2009 __________________________________ __________________________________ Jeffrey D. Evanseck Ellen Gawalt Professor of Chemistry and Biochemistry Assistant Professor of Chemistry and Dissertation Director Biochemistry Committee Member Committee Member __________________________________ __________________________________ Douglas J. Fox -
Defining Active Ingredient: the U.S
Defining Active Ingredient: The U.S. Food and Drug Administration’s Legal Interpretation of Regulatory Exclusivities December 10, 2019 Congressional Research Service https://crsreports.congress.gov R46110 SUMMARY R46110 Defining Active Ingredient: The U.S. Food and December 10, 2019 Drug Administration’s Legal Interpretation Erin H. Ward Legislative Attorney of Regulatory Exclusivities Whether many provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) apply to a particular drug product turns in part on the novelty of the “active ingredient” of the drug in question. In particular, the Food and Drug Administration (FDA) must assess the novelty of the active ingredient in a new drug, comparing it to a previously approved drug’s active ingredient to determine whether the new drug qualifies for the five-year “new chemical entity” (NCE) exclusivity. FDA generally cannot accept new drug applications that refer to a drug with NCE exclusivity (i.e., rely on its clinical data and FDA’s approval of the drug) for five years. Companies that receive approval for drugs with new active ingredients generally enjoy a competitive advantage in the market while the exclusivity is in effect—and after, depending how long it takes for generic versions to receive approval once applications can be submitted. Comparing active ingredients can be technically quite complicated. For instance, compounds in a final drug product may convert to other compounds through chemical reactions inside the body before arriving at the site of the therapeutic effect. In addition, related but distinct drug molecules may be clinically indistinguishable or convert into the same pharmacologically or physiologically active component inside the body. -
Isobutene Formation from 3-Hydroxy-3-Methylbutyrate (3-HMB
Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2011 Isobutene formation from 3-hydroxy-3-methylbutyrate (3-HMB) by the Saccharomyces cerevisiae diphosphomevalonate decarboxylase (ScMDD) and directed enzyme evolution to improve enzyme function David Gogerty Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Biochemistry, Biophysics, and Structural Biology Commons Recommended Citation Gogerty, David, "Isobutene formation from 3-hydroxy-3-methylbutyrate (3-HMB) by the Saccharomyces cerevisiae diphosphomevalonate decarboxylase (ScMDD) and directed enzyme evolution to improve enzyme function" (2011). Graduate Theses and Dissertations. 10353. https://lib.dr.iastate.edu/etd/10353 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Isobutene formation from 3-hydroxy-3-methylbutyrate (3-HMB) by the Saccharomyces cerevisiae diphosphomevalonate decarboxylase (Sc MDD) and directed enzyme evolution to improve enzyme function by David Gogerty A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Biochemistry Program of Study Committee: Thomas A. Bobik, Major Professor Alan DiSpirito Basil Nikolau Donald Beitz Robert Brown Iowa State University Ames, Iowa 2011 Copyright © David Gogerty, 2011. All rights reserved. ii TABLE OF CONTENTS LIST OF FIGURES v LIST OF TABLES viii ACKNOWLEDGEMENTS ix ABSTRACT xi CHAPTER 1. General Introduction 1 I. -
Relevance of N-Nitroso Compounds to Human Cancer: Exposures and Mechanisms
WORLD HEALTH ORGANIZATION ' Ю INTERNATIONAL AGENCY FOR RESEARCH ON CANCER RELEVANCE OF N-NITROSO COMPOUNDS TO HUMAN CANCER: EXPOSURES AND MECHANISMS Proceedings of the IXth International Symposium on N-Nitroso Compounds, held in Baden, Austria, 1-5 SeptemЬеr 1986 Co-sponsored by: National Cancer Institute (USA) Dr M. Okada Giapan) and associated Japanese industrial sponsors Thermedics Inc. (USA) Ciba-Geigy (Switzerland) Imperial Chemical Industries (UK) EDITORS H. BARTSCH, T.K. 0 NЕILL & R. SCHULTE-HERMANN JAR SCIENTIFIC PUBLICATIONS NO. 84 INTERNATIONAL AGENCY FOR RESEARCH ON CANCER LYON 1987 CONTENTS Foreword.................................................................. 1 Introduction................................................................ 3 Overview................................................................... 5 Keynote address P.N. Magee ............................................................. 11 1. MOLECULAR AND BIOCHEMICAL MECHANISMS Biochemical events in nitrosamine-induced hepatocarcinogenesis: relevance of animal data to human carcinogenesis R.Schulte-Hermann .....................................................17 Biochemical and molecular effects of N-nitroso compounds in human cultured cells: an overview C.C. Harris .............................................................20 Activation of the human c-Ha-ras-1 proto-oncogene by in-vitro reaction with N-nitroso- methyl(acetoxymethyl)amine S. Hirani-Hojatti, J.R. Milligan & M.C. Archer ..............................26 Specificity of OЬ-alkylguanine-DNA -
Division of Organic Chemistry
ORGN DIVISION OF ORGANIC CHEMISTRY S. Silverman and E. McLaughlin, Program Chairs SUNDAY MORNING Section A Pennsylvania Convention Center 116 New Reactions & Methodology S. M. Silverman, Organizer 8:00 1. Copper catalyzed reductive carbonylation of alkyl iodides. S. Zhao, N.P. Mankad 8:20 2. Sulfenate-anion-catalyzed diastereoselective aziridination of imines. Z. Zheng, P.J. Walsh 8:40 3. Cyanoalkylcopper species in carbon-carbon bond forming reactions. D.L. Silverio 9:00 4. New reactivity enabled by cation-π interactions. P.J. Walsh 9:20 5. Dipolar alkynyl-prins (DAP) cyclization for the rapid construction of complex polycycles. S. Abdul-Rashed, G. Alachouzos, A. Frontier 9:40 6. Subphthalocyanines and perylene-diimide derivatives in organic photovoltaics. L. Chockalingam Kasi Viswanath 10:00 7. Silylated α-aminonitriles for late-stage functionalization. T. Mathew, T. Yamato, S.G. Prakash 10:20 8. Synthesis of differentially substituted diynes via tandem nucleophilic addition/fragmentation pathways. A. Tavakoli, G.B. Dudley 10:40 9. Analogues of Bestmann’s ylide, Ph3P=C=C=O: Syntheses, structures and Lewis acid catalyzed cyclizations with organic substrates. C. Krempner 11:00 10. Diastereoselective alkynylations of β-(Bromo)iminium ions via copper(I) catalysis. S.O. Santana, W. Guan, M.P. Watson 11:20 11. Modular three-component difunctionalization of aryl/cyclohexenyl triflates via arynes and cyclohexynes. S. Cho, Q. Wang 11:40 12. 1,2-aminocyanation of alkenes via distal migration. Y. Kwon, Q. Wang Section B Pennsylvania Convention Center 117 Heterocycles & Aromatics S. M. Silverman, Organizer 8:00 13. Formal [4+2] cycloaddition between alkynes and allene-ynes to generate functionalized toluenes. -
Chemical Synthesis of Staphyloferrin B Affords
Chemical Synthesis of Staphyloferrin B Affords Insight into the Molecular Structure, Iron Chelation, and Biological Activity of a Polycarboxylate Siderophore Deployed by the Human Pathogen The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Madsen, Julie L. H., Timothy C. Johnstone, and Elizabeth M. Nolan. “ Chemical Synthesis of Staphyloferrin B Affords Insight into the Molecular Structure, Iron Chelation, and Biological Activity of a Polycarboxylate Siderophore Deployed by the Human Pathogen Staphylococcus Aureus .” Journal of the American Chemical Society 137, no. 28 (July 22, 2015): 9117-9127. As Published http://dx.doi.org/10.1021/jacs.5b04557 Publisher American Chemical Society (ACS) Version Author's final manuscript Citable link http://hdl.handle.net/1721.1/104954 Terms of Use Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. Chemical Synthesis of Staphyloferrin B Affords Insight into the Molecular Structure, Iron Chelation, and Biological Activity of a Polycarboxylate Siderophore Deployed by the Human Pathogen Staphylococcus aureus Julie L. H. Madsen,a Timothy C. Johnstonea and Elizabeth M. Nolana,* aDepartment of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA *Corresponding author: [email protected] Phone: 617-452-2495 Fax: 617-324-0505 1 Abstract Staphyloferrin B (SB) is a citrate-based polycarboxylate siderophore produced and utilized by the human pathogen Staphylococcus aureus for acquiring iron when colonizing the vertebrate host. The first chemical synthesis of SB is reported, which enables further molecular and biological characterization and provides access to structural analogues of the siderophore. -
NDA Classification Codes
MANUAL OF POLICIES AND PROCEDURES CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 5018.2 POLICY AND PROCEDURES Office of Pharmaceutical Quality NDA Classification Codes Table of Contents PURPOSE ..............................................................................1 BACKGROUND ...................................................................1 POLICY .................................................................................1 NDA Classification Codes ...................................................2 RESPONSIBILITIES ...........................................................7 REFERENCES ......................................................................9 DEFINITIONS ......................................................................9 EFFECTIVE DATE ............................................................10 CHANGE CONTROL TABLE ..........................................10 PURPOSE This MAPP describes the new drug application (NDA) classification code assigned by the Center for Drug Evaluation and Research (CDER) to an NDA based on characteristics of the product in the application. This code was previously referred to as “Chemistry Classification Code.” BACKGROUND • The NDA classification code provides a way of categorizing new drug applications. The code evolved from both a management and a regulatory need to identify and group product applications based on certain characteristics, including their relationships to products already approved or marketed in the United States. Classifying applications based on these -
Fda-2009-N-0184-00341
DE PART:\-lENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Rockville, MD 20857 , 0 '1 NDA 021977 \ \ 1-'? ~ ,0 Chad A. Landmon Axinn Veltrop & Harkrider LLP 90 State House Square Hartford, CT 06103-3702 Docket No. FDA-2009-N-0184 Dear Mr. Landmon: Actavis Elizabeth LLC ("Actavis") has requested that the Food and Drug Administration ("FDA" or "Agency") reconsider its grant of new chemical entity exclusivity to Vyvanse (Iisdexamfetamine dimesylate) Capsules under sections 505(c)(3)(E)(ii) and 505U)(5)(F)(ii) of the Federal Food, Drug, and Cosmetic Act ("FDCA" or "the Act") and the implementing regu1ation at 21 CFR § 314.108. Actavis asserts that FDA should have granted Vyvanse a shorter period ofexclusivity under sections 505(c)(3)(E)(iii) and 505U)(5)(F)(iii) of the Act, and permitted the company to submit its abbreviated new drug application ("ANDA") for lisdexamfetamine dimesylate ("lisdexamfetamine") on January 28, 2009. We have carefully reviewed the submissions made to the Agency on this issue and additional relevant materials. For the reasons set forth below, we deny Actavis' request and affirm that lisdexamfetamine is entitled to NCE exclusivity. I. Summary Vyvanse Capsules contain lisdexamfetamine dimesylate as the active ingredient. Lisdexamfetamine consists of dextroamphetamine bonded covalently to lysine through an amide bond. Lisdexamfetamine is a prodrug that is metabolically converted to produce dextroamphetamine, which is responsible for the drug's activity. Under FDA's regulation at 21 CFR § 314.108, a non-ester covalently bonded molecule is considered the active moiety ofa drug and, if not previously approved, it will be considered a new chemical entity entitled to 5 years of exclusivity. -
The Prodrug Approach: a Successful Tool for Improving Drug Solubility
Review The Prodrug Approach: A Successful Tool for Improving Drug Solubility Daniela Hartmann Jornada, Guilherme Felipe dos Santos Fernandes, Diego Eidy Chiba, Thais Regina Ferreira de Melo, Jean Leandro dos Santos and Man Chin Chung * Received: 14 October 2015 ; Accepted: 15 December 2015 ; Published: 29 December 2015 Academic Editors: Thomas Rades, Holger Grohganz and Korbinian Löbmann Faculdade de Ciências Farmacêuticas, UNESP—University Estadual Paulista, Rodovia Araraquara Jaú Km 01, 14801-902 Araraquara, São Paulo, Brasil; [email protected] (D.H.J.); [email protected] (G.F.S.F.); [email protected] (D.E.C.); [email protected] (T.R.F.M.); [email protected] (J.L.S.) * Correspondence: [email protected]; Tel.: +55-16-3301-6962; Fax: +55-16-3301-6960 Abstract: Prodrug design is a widely known molecular modification strategy that aims to optimize the physicochemical and pharmacological properties of drugs to improve their solubility and pharmacokinetic features and decrease their toxicity. A lack of solubility is one of the main obstacles to drug development. This review aims to describe recent advances in the improvement of solubility via the prodrug approach. The main chemical carriers and examples of successful strategies will be discussed, highlighting the advances of this field in the last ten years. Keywords: prodrug; solubility; water-soluble prodrugs; solubility of prodrugs; molecular modification 1. Introduction Poor solubility is one of the main problems faced by researchers during drug development. Commonly, even with the use of current computational “filters” to minimize this problem, compounds that are active in vitro may lack adequate pharmacokinetic properties and/or may be difficult to formulate [1]. -
Novel Fidaxomicin Antibiotics Through Site-Selective Catalysis
ARTICLE https://doi.org/10.1038/s42004-021-00501-6 OPEN Novel fidaxomicin antibiotics through site-selective catalysis ✉ David Dailler1,4, Andrea Dorst1,4, Daniel Schäfle2, Peter Sander2,3 & Karl Gademann 1 Fidaxomicin (FDX) is a marketed antibiotic for the treatment of Clostridioides difficile infec- tions (CDI). Fidaxomicin displays antibacterial properties against many Gram-positive bac- teria, yet the application of this antibiotic is currently limited to treatment of CDI. Semisynthetic modifications present a promising strategy to improve its pharmacokinetic properties and also circumvent resistance development by broadening the structural diversity of the derivatives. Here, based on a rational design using cryo-EM structural analysis, we 1234567890():,; implement two strategic site-selective catalytic reactions with a special emphasis to study the role of the carbohydrate units. Site-selective introduction of various ester moieties on the noviose as well as a Tsuji–Trost type rhamnose cleavage allow the synthesis of novel fidaxomicin analogs with promising antibacterial activities against C. difficile and Mycobacterium tuberculosis. 1 Department of Chemistry, University of Zurich, Zurich, Switzerland. 2 Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland. 3 National Center for Mycobacteria, University of Zurich, Zurich, Switzerland. 4These authors contributed equally: David Dailler, Andrea Dorst. ✉ email: [email protected] COMMUNICATIONS CHEMISTRY | (2021) 4:59 | https://doi.org/10.1038/s42004-021-00501-6 | www.nature.com/commschem 1 ARTICLE COMMUNICATIONS CHEMISTRY | https://doi.org/10.1038/s42004-021-00501-6 idaxomicin (1, tiacumicin B, lipiarmycin A3) constitutes an Over the past few decades, derivatization of natural products 18-membered narrow-spectrum macrolide antibiotic that was has been demonstrated to be an effective approach for the F 1–7 21 extracted from several actinomycetes and shows anti- development of new drug candidates .